Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML, Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA.: J Clin Oncol 2004;22:909–18